Exciting new screening and staging modalities, management approaches and emerging treatment options.

Transcription

1 Organized for Organized for November 18-19, 2011 Chair: Exciting new screening and staging modalities, management approaches and emerging treatment options. Second Announcement W W W. I M E D E X. C O M

2 November 18-19, 2011 Dear Colleague: Please join me in New York City this November for the 16 th Annual Perspectives in Thoracic Oncology! 16 Years of Exceptional Educational Value: Perspectives in Thoracic Oncology has become the premier source for updates in thoracic oncology; we readily recognize the burgeoning need among thoracic oncology clinicians and researchers for the latest information on the complex biology and treatment of lung cancer. This conference provides a forum to update your knowledge in the field, confirm your current practices and receive valuable take-home information on exciting new screening and staging modalities, management approaches, and emerging treatment options. Significant Impact on Clinical Practice: Nearly 200 physicians, nurses, and other healthcare professionals attend Perspectives in Thoracic Oncology annually. Past participants value the scope and depth of the information on disease biology, management, and research presented, and many return year after year for the newest updates. Distinguished Faculty and Networking Opportunities: In this educational setting, you will have valuable opportunities to interact with your colleagues and learn from renowned faculty, key thought leaders in thoracic oncology, as well as network with the diverse mix of oncologists, surgeons, and pulmonologists who attend. This fall s conference, to be held November 18-19, 2011, promises to be our most exciting meeting yet. I hope to see you there! Sincerely,, Chair

3 5:15 pm Adjourn Faculty Wallace Akerley, MD Huntsman Cancer Institute University of Utah Salt Lake City, Utah Chandra P. Belani, MD Penn State Hershey Cancer Institute Hershey, Pennsylvania Jeffrey D. Bradley, MD Washington University School of Medicine St. Louis, Missouri Jessica S. Donington, MD, MSCR New York University School of Medicine David S. Ettinger, MD, FACP, FCCP Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Baltimore, Maryland Tracey L. Evans, MD Abramson Cancer Center Barbara Gitlitz, MD University of Southern California Keck School of Medicine Los Angeles, California Rogerio C. Lilenbaum, MD Cleveland Clinic Florida Weston, Florida R. Nevin Murray, MD, FRCPC British Columbia Cancer Agency Vancouver, BC, Canada Suresh S. Ramalingam, MD Winship Cancer Institute Emory University Atlanta, Georgia Charles M. Rudin, MD, PhD The Sidney Kimmel Comprehensive Cancer Center John Hopkins University Baltimore, Maryland Howard Safran, MD Brown University Oncology Group Providance, Rhode Island Beth Eaby Sandy, CRNP Mitchell Schnall, MD, PhD Ramaswamy Govindan, MD Washington University School of Medicine St. Louis, Missouri Lecia V. Sequist, MD, MPH Harvard Medical School Massachusetts General Hospital Boston, Massachusetts Nasser H. Hanna, MD Indiana University Indianapolis, Indiana Gerard A. Silvestri, MD, MS Medical University of South Carolina Charleston, South Carolina Daniel D. Karp, MD University of Texas M. D. Anderson Cancer Center Houston, Texas Anne S. Tsao, MD University of Texas M. D. Anderson Cancer Center Houston, Texas Maria Werner-Wasik, MD Thomas Jefferson University & Hospital

4 Scientific Agenda Friday, November 18, 2011 Session I: Introductory lectures 8:00 am Welcome Corey J. Langer, MD FACP 8:10 am Lung cancer screening in 2011: Current reality post completion of the National Lung Cancer Screening Trial Mitch Schnall, MD, PhD 8:30 am 8:50 am Session III: Radiation oncology for the uninitiated and perpetually perplexed 12:40 pm 12:45 pm Economics and therapeutic implications of lung cancer screening in the modern era Speaker invited State-of-the-art combined modality therapy 1:05 pm Pathology: What is the most effective and practical way of assessing molecular markers? Ramaswamy Govindan, MD Integrating modern imaging and technology with therapy in locally advanced NSCLC (LA-NSCLC) Jeffrey D. Bradley, MD 1:25 pm Novel approaches to radiation therapy in the palliative settings Maria Werner-Wasik, MD 1:45 pm of the 9:10 am Panel discussion and knowledge/ 9:30 am Break Session II: Surgery and staging Session IV: Prevention and early stage NSCLC 9:50 am confidence assessment of the audience via ARS survey 2:05 pm 9:55 am The intricacies of staging in NSCLC Gerard A. Silvestri, MD, MS 2:10 pm 10:15 am Debate: Surgery versus radiation therapy in patients with operable early-stage NSCLC Surgeon s perspective Jessica S. Donington, MD, MSCR Rethinking strategies for chemoprevention in lung cancer Daniel D. Karp, MD 2:30 pm Adjuvant therapy: State of the art in 2011 Tracey L. Evans, MD 2:50 pm Ongoing clinical trials in the adjuvant arena Speaker invited Radiation oncologist s perspective Jeffrey D. Bradley, MD 10:45 am of the 3:10 pm of the 11:05 am Lunch 3:30 pm Break Session V: Special topics in thoracic oncology 3:50 pm Esophageal cancer: Therapeutic updates Howard Safran, MD 4:10 pm New insights in the management of mesothelioma Anne S. Tsao, MD 4:30 pm SCLC: An orphan disease. Who will adopt? Charles M. Rudin, MD, PhD 4:50 pm Updates on thymoma Tracey L, Evans, MD 5:10 pm Panel discussion and knowledge/confidence assessment of the 5:30 pm Closing notes and adjourn

5 Saturday, November 19, 2011 Session VI: Advanced NSCLC Session VII: Supportive therapy 8:00 am Welcome to day two 12:40 pm 8:05 am Practical tips on the management of toxicities with EGFR and VEGFR inhibitors Beth Eaby Sandy, CRNP 1:00 pm Controversies regarding the use of growth factor support in the treatment of cancer Beth Eaby Sandy, CRNP 1:20 pm Management of bone metastases in NSCLC David S.Ettinger, MD, FACP, FCCP 1:40 pm Panel discussion and knowledge/ 8:10 am Using histology to personalize therapy Nasser H. Hanna, MD 8:30 am Role of EGFR TKIs as frontline therapy in mutation positive patients with NCSLC Lecia V. Sequist, MD, MPH 8:50 am Is ERCC1 and RRM1 ready for prime time? Ramaswamy Govindan, MD 9:10 am of the 9:30 am Break 9:50 am 9:55 am Debate: What is the optimal extended therapy approach? Switch maintenance therapy Chandra P. Belani, MD Continuation maintenance Tracey L. Evans, MD No maintenance Nasser H. Hanna, MD 10:40 am 11:00 am Therapeutic options in the salvage setting Barbara Gitlitz, MD Current therapeutic paradigm in patients with compromised performance status Rogerio C. Lilenbaum, MD, FACP Session VIII: Biomarkers 2:00 pm 2:05 pm EML4/ALK and other new biomarkers and their therapeutic implications Lecia V. Sequist, MD, MPH 2:25 pm The expanding role of proteomics Wallace Akerley, MD 2:45 pm of the 3:05 pm Break Session IX: Targeted therapies 3:25 pm 3:30 pm Angiogenesis inhibition: Bevacizumab and beyond Suresh S. Ramalingam, MD 11:20 am of the 3:50 pm MET kinase inhibitors as therapeutic agents Suresh S. Ramalingam, MD 11:40 am Lunch 4:10 pm New targeted agents on the horizon Charles M. Rudin, MD, PhD 4:30 pm Immunotherapy: Has its time arrived? R. Nevin Murray, MD, FRCPC 4:50 pm of the 5:10 pm Closing notes Visit to register.

6 AUDIENCE PARTICIPATION: A HANDS-ON EXPERIENCE During the scientific sessions, speakers and the audience can exchange information through a hands-on computerized speaker-audience interaction system. With this state-of-the-art equipment, participants answer multiple choice questions, and within seconds, the answers are calculated and projected on a screen in tabular or graphic form for all to see. This system maximizes the ability for attendees from diverse disciplines to see differing opinions and compare consensus between the speakers and each other. Continuing Medical Education Support Imedex, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Imedex, LLC designates this live educational activity for a maximum 12.0 of AMA PRA Category 1 CreditsTM. Physicians should claim only credit commensurate with the extent of their participation in the activity. The following companies have provided an educational grant in support of this conference: Who Should Attend Gold This educational activity is specifically designed for medical oncologists, radiation oncologists, thoracic surgeons, pulmonologists, nurses, and other physicians, clinicians, and health care professionals involved and/or interested in the therapeutic management of patients with lung cancer and other thoracic malignancies. Silver Platinum Genentech BioOncology and OSI Oncology Objectives After successful completion of this course, participants should be able to: Have increased awareness/knowledge regarding: o Advances in lung cancer prevention, including novel chemopreventive strategies and new understanding of the role of smoking o Ongoing trials and novel approaches to adjuvant therapy for lung cancer Have increased confidence in their ability to: o Use surgical and nonsurgical techniques to accurately stage lung cancer o Manage resectable, high-risk, or inoperable lung cancer with single or combined modalities o Diagnose and manage rare thoracic cancers, such as esophageal cancer, mesothelioma, small-cell lung cancer, and thymoma o Manage advanced NSCLC in the frontline, maintenance, and salvage settings o Provide supportive care for patients with lung cancer, including management of therapy-related side effects and treatment of bone metastases Increase the frequency (compared with current) with which they plan to: o Use mutation status and other biomarkers to predict outcomes and select optimal treatments for each patient o Enroll patients in clinical trials of novel agents or new indications for existing agents Corporate Several options are available to companies interested in supporting this conference. For more information, please contact Imedex at +1 (770) or by at cme@imedex.com. Call for Exhibitors Exhibit space is available to companies interested in participating in this conference. For more information, please contact Imedex at +1 (678) or by at exhibits@imedex.com.

7 Registration Rates Early Payment received by September 22, 2011 Discounted Payment received by November 10, 2011 Regular Payment received after November 10, 2011 Group discount (physicians only)* *Cannot be combined with any other discounts Nurses/Residents/Students* *Proof of eligibility must accompany registration; cannot be combined with any other discounts $250 $350 $450 November 18-19, $50 $99 Registration HOTEL ACCOMMODATIONS To Register: You may register online by November 10, 2011 at by calling Imedex at +1 (678) or by returning the registration form in this program by mail or fax. If you mail the form, please keep a copy for your records. Registration confirmations will be issued before the meeting. New York Marriott Downtown 85 West Street at Albany 10006, USA Tel.: +1 (212) Fax: +1 (212) To qualify for special registration fees, registration and full payment must be received by Imedex by the dates specified. Group Discounts: Each one of multiple registrants from the same institute or practice each receive a $50 discount off the published registration fees, provided all registration forms and payments are received together. Only one discount will apply per physician. Discounts are not available for Nurses/ Residents/Students. Payment: To pre-register, registration and payment must be received no later than November 10, Please register onsite after this date. Contact Imedex at +1 (678) or visit our website at www. imedex.com to ensure the course is being held as scheduled and to confirm that the meeting is not full. Registration fees must be remitted by credit card or check. Checks should be payable to Imedex. Attendee is not registered until full payment is received. Registration Fee Inclusions: Registration fees include admittance to all scientific sessions, conference materials, processing of certificates of attendance or continuing medical education, and all event functions as specified in the agenda. Cancellation: For registration fees to be refunded, written notice of cancellation must be received at meetings@imedex.com no later than November 10, The amount of registration fees remitted, minus a $75 administrative charge, will be refunded after the conference. Substitutions are accepted with written notification. No refunds will be made if notice is received after November 10, Imedex does not accept responsibility for covering travel, accommodation or any other costs incurred by registrants in the rare event that this meeting should be canceled for any reason. Every effort will be made to give reasonable notice in the event of cancellation. The event agenda is subject to change without notice. The New York Marriott Downtown is a premier downtown Manhattan hotel previously named the New York Marriott Financial Center. In addition to offering an abundance of New York City vacation packages, they provide a superior level of luxury and service among hotels in downtown Manhattan. Ideally located in the heart of NYC s Financial District, with easy access to the World Trade Center site, Statue of Liberty, Ellis Island, South Street Seaport, and SOHO NYC, the downtown Manhattan hotel is perfect for business trips, weekend getaways or leisure travel alike. The downtown Manhattan hotel near Battery Park offers 497 richly appointed hotel rooms, complete with the new luxurious Revive bedding, and also features the 85 West Sports Bar and Grill. For the convenience of attendees, a room block with a limited number of rooms has been reserved at the discounted group rate of $229 single/double occupancy, plus tax, currently at 14.75% plus a $3.50 occupancy tax. This limited number of discounted rooms will be available until October 28, This discounted rate is not guaranteed outside the conference dates. Reservations received after October 28, 2011 or after the room block has been filled (whichever comes first) are subject to availability and prevailing hotel rates. To reserve your room please contact the New York Marriott Downtown reservations department toll free 1 (800) or local phone 1 (506) To receive the group rate, callers must identify themselves as being with the Imedex/16th Annual Perspectives in Thoracic Oncology group. To make a room reservation online, please visit the following website: passkey.com/resweb.do?mode=welcome_ei_ new&eventid= Reservation requests received after October 28, 2011 may not be guaranteed the group rate.

8 November 18-19, 2011 Important Dates Early Registration September 22, 2011 Hotel Group Rate October 28, 2011 Discounted Registration November 10, 2011 Presentation Dates November 18-19, 2011 REGISTRANT INFORMATION A FIRST NAME MI LAST NAME DEGREE: MD PhD PharmD RN Other SPECIALTY: Medical Oncology Nursing Pulmonology Radiation Oncology Surgery Other ADDRESS TELEPHONE FAX INSTITUTE DEPARTMENT ADDRESS CITY STATE/PROVINCE ZIP/POSTAL CODE COUNTRY Registration Fees Early Payment received by 9/22/2011 $250 Discounted Payment received by 11/10/2011 $350 Payment Method American Express MasterCard Visa Check in the amount of $ CARDHOLDER S NAME SIGNATURE Regular Payment received after 11/10/2011 $450 Group discount (physicians only) -$50 Nurses/Residents/Students $99 CARD NUMBER EXP. DATE Check if you require special facilities or assistance and attach a note with specific details and requirements. NOTE: After November 10, 2011 only credit card payments will be accepted for pre-registration. To pre-register, registration and payment must be received no later than November 10, Please register onsite after this date. Contact Imedex at +1 (678) or visit our website at to ensure that the meeting is being held as scheduled and to confirm that the meeting is not full. Cancellation: For registration fees to be refunded, written notice of cancellation must be received at meetings@imedex.com no later than November 10, The amount of registration fees remitted, minus a $75 administrative charge, will be refunded after the conference. Substitutions are accepted with written notification. No refunds will be made if notice is received after November 10, Rainwater Drive, Suite 600 Alpharetta, Georgia 30009, USA Imedex is a brand and assumed name used by Imedex, LLC (hereby referred to as Imedex). Imedex is solely responsible for this agenda s content. Although Imedex attempts to ensure that the information in our program is accurate and timely, matters and opinions discussed and/or presented with respect to clinical matters are those of the discussion participants only, and not necessarily those of Imedex. Moreover, although Imedex attempts to identify and integrate the most qualified medical professionals in our program, TO THE FULLEST EXTENT PERMITTED BY LAW, IMEDEX EXPRESSLY DISCLAIM ALL WARRANTIES, EITHER EXPRESS OR IMPLIED, STATUTORY OR OTHERWISE, INCLUDING BUT NOT LIMITED TO THE IMPLIED WARRANTIES OF MERCHANTABILITY, NON-INFRINGEMENT OF THIRD PARTIES RIGHTS, AND FITNESS FOR A PARTICULAR PURPOSE, WITH RESPECT TO THE CONTENT PRESENTED. IMEDEX FURTHER MAKES NO REPRESENTATIONS OR WARRANTIES ABOUT THE ACCURACY, RELIABILITY, COMPLETENESS OR TIMELINESS OF THE CONTENT OR ANY MATERIAL PRESENTED. In addition, the material presented and related discussions are not intended to be medical advice, and the presentation or discussion of such material is not intended to create and does not establish a physician-patient relationship. Medical advice of any nature should be sought from an individual s own physician. Neither Imedex nor any of its subsidiaries or affiliates is affiliated with or formally endorsed by a medical society Imedex, LLC. All rights reserved. Reproduction in whole or part is prohibited without prior written consent from Imedex and contributing faculty.